Lantheus Holdings Inc (LNTH) Cash Flow Statement
A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide.
Total Cash From Operating Activities Chart for Lantheus Holdings Inc
Lantheus Holdings Inc (LNTH) operating cash flow for FY2025 was USD 390.1M, a -28.4% change from FY2024. Lantheus Holdings Inc's operating cash flow grew from USD 23.2M in 2011 to USD 390.1M in 2025 (1581.0% over 14 years). Operating cash flow compound annual growth rate: 5-year CAGR of 88.5%, 10-year CAGR of 33.5%.
Total Cash From Operating Activities (US Dollars)
R&D as % of Revenue
Key Stats
- Market Cap
- $6.53B
- Implied Share Price
- $99.95
- Enterprise Value
- $6.56B
- Revenue (TTM)
- $1.56B
- EBITDA
- $392.22M
- Profit Margin
- 17.69%
- Trailing P/E
- 24.20
- Forward P/E
- 14.27
- Price/Book (MRQ)
- 4.98
- Price/Sales (TTM)
- 4.19
- EV/EBITDA
- 13.92
- EV/Revenue
- 4.22
- Dividend Yield
- —
- Book Value
- $20.10
- Free Cash Flow (FY2025)
- $354.05M
- Free Cash Flow Yield
- 5.42%
Snapshot as of 7th October 2026 — not point-in-time controlled, may lag the live market by a few days.